


"I4RD strengthens R&D activities in India, Israel"

05 May 2010 | News





Innovation is the key for companies to gain advantage over their competitors in medium to long term basis. Strengthening R&D is one of the ways to achieve the required innovation. Further, R&D serves as an enhancer for sustained economic growth. R&D on a global scale helps to share risks as well as costs; shortens development time and time to market; and provides access to global 1 infrastructure.

Recognizing the need for collaborative R&D, India and Israel have signed a bilateral agreement, to form India – Israel Initiative for Industrial R&D (i4RD) with an aim to support joint industrial R&D projects for developing products or processes leading to commercialization in the global market. signed between the Department of Science and Technology (DST),

Ministry of Science and Technology, Government of India and the Ministry of Industry, Trade and Labor State of Israel. John Powath, CEO, Inventive Business Partners and head of i4RD program

shares more insights.

Q What are the major collaborative activities of i4RD program?

The i4RD program is a bilateral funding program that is co-sponsored by the governments of India and Israel with a primary aim to support joint industrial R&D projects for developing products or processes for commercialization in the global market. This bilateral funding platform is supporting R&D projects between companies in Israel and India. This program will provide a platform for joint R&D efforts that has a strong emphasis on innovation with a global commercial applicability.

The implementing organizations are Global Innovation and Technology Alliance (GITA) on behalf of the DST, India; and MATIMOP, on behalf of the Office of the Chief Scientist (OCS), Israel.

Q Does the political landscape of India encourage such collaboration?

IndiandraaheeadintgwardagtowinegconomicooperatioBilateraradev,hickhaBB93.4330 (\$200 mmi@000gretBa58,316 ron (\$4.11 mi@009e,xcludindgefensteadeT.hiscludessanufacturings,atellite launcagricultuzeratiamoniddustriefArmarteeadegreemewtapprogresB01f@ro-waagreement thatoulgivediaindustriezccestbeleraetligtechnologs,ectoamletraeccestbalaron ket. ThistepheadhPereferentiaTradAgreement(PTAthatecommendssettingsbirStud@rou(JSG))

the two countries to improve trade ties.

isstimatethatilateraladoroulexceeRS3,605ror(\$12nij)veanvitthisadagreemenT.hareas thagevemphasiseftwarcommunicationomelasecuriscienaendedicinaeigro-technologies andateConsideringthesfacts4RprograjasibtlateraIndingrograantdeinaeoliticianhpediments

for such collaborations.



nancial support offered by the i4RD program?

Therograprovid feam dingfperce bl& CostFurthetheienveratlap founding/hielstimatells:230(\$500,000) projectetweethediamd Israetiompanielsas jesti Rt& Dojectepprovet of the diatistration Ristro(\$250,000) outstagenset by diatistration titilization spective

Theritertifellow end explight RCalle--tetatyteciencertechnology companie the spective untrist south predster store petities earch and evelopment produce procest peroject any volve of the ame company examples, a demie search tit as ignitude b-contractors prods betwight you vative b price and more prods betwight you wat we bound in the search and the

projeshouladatevelopingroductp/ocesseleadintgpmmercializatidhgelobarlarkeatntdperoject

partners should agree in advance on the IP rights and commercialization strategy of the product or process.

Fromidia/serspectiv/###igib#pplican#seesearcheasedanagerespresentin/gdiacompani@with minimus/precent/nershit//alteadquarter/ind/and/gisteren/derdia/compani@s3:ubsidiaries/ firm/seadquarterea/hol/neo/utsidediareetigib/suppos3:o/aroprietorshippartnership/mareot eligiblie/undingupporT.hkediain/dustry/artnernustavarR&Dentev/hidhasaline/cognitio/inon/hhe Departmes/ficientifian/ddustri&lesear(DSIRG)overnmes/ficient/firshoughtR&D cent@S/k@cognizer/th/m2ont/astsendiragpplicatio/deR/Dailinvg/hich.nlessod/herwisextended,


the firm may be asked to return the loan amount.


Theotalundingontheovernmentlindiavitlexceeopercentlihendiacomponentliheotaprojectost. FurthetheotalundingontheovernmentlisraetitheCSundethiaRDnancialuppontvitlexceeo0

percent of the eligible and approved costs of the R&D, in accordance with the national laws and regulations

Q What will happen if the project fails to bring positive result?

IncasethendesubtheR&Defforing of ruitfulther evoul de one edpa back-lowever itheR&Defforing fruitfulther evoul de equirement beturthe gram trovide typicallighteor rotation terest teles a comminimal see to five years.





ners for innovative firms in India?

The proximity of research institutes, large firms and start-ups, a talent pool drawn from around the world, a friendly ecosystem of venture capital, and government initiatives to encourage R&D through unilateral and bilateral

Israel has the highest number of scientists per capita globally (1/200 people), and 39 percent of its scientists specialize in life sciences. Moreover, with a high percentage of graduates in mathematics, physics and computer sciences, the industry is well placed to make an impact in interdisciplinary technologies such as bioinformatics and proteomics.

Israel has also taken a world-leading role in cancer and auto-immune disease research, as well as research into diseases affecting the central nervous system. Half of all the Israeli biotech companies are very small, with no more than 20 employees. Inspite of the outstanding growth of this sector it is still in early stages and the potential is much larger than current activity. Thus, there appears a definite potential match perspective between Indian and Israeli biotech companies. The same would also be true for other fields of science and technology.

Biotech companies in general face the problem of raising working capital because of their small size and long lead-time to market. The financial crisis makes it even more difficult for them to get the fund assistance. This opportunity can be capitalized by innovative companies in India to access funding as well as R&D talent pool through the joint R&D funding program.

Q Are life sciences firms in Israel less likely to cooperate/ partner with foreign institutions than domestic firms?

If we look from an Indian perspective, one could form the view that the chances of two local Indian companies collaboratingis far greater than a potential collaboration between a local and foreign company. Cooperation or collaboration needs to be a mutually beneficial relationship. So it would have to be a win-win situation for both sides.

India has a large domestic market, the R&D collaboration can definitely benefit Israeli companies as those companies get access to Indian market through their collaborating partner in India and the Indian companies get access to diverse R&D talent pools in Israel that could potentially shorten the development time and boost innovation.

Jahanara Parveen in Bangalore